Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

231.27USD
19 Jul 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$231.27
Open
$232.86
Day's High
$234.10
Day's Low
$231.20
Volume
478,208
Avg. Vol
834,682
52-wk High
$388.67
52-wk Low
$216.13

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $44,841.73
Shares Outstanding(Mil.): 193.89
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 9.91 30.63 34.52
EPS (TTM): 23.33 -- --
ROI: 20.60 13.02 12.69
ROE: 33.64 14.18 17.17

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

15 May 2019

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

15 May 2019

UPDATE 1-NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

15 May 2019

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

15 May 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

25 Apr 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

25 Apr 2019

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

24 Apr 2019

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

24 Apr 2019

UPDATE 3-Biogen dips as strategy post Alzheimer's setback fails to impress

* Co beats 1st-qtr profit and revenue estimates (Adds details from conference call, analyst comment)

24 Apr 2019

Biogen first-quarter profit rises 20 percent

April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.

24 Apr 2019

Earnings vs. Estimates